Fibrosis in tissue engineering and regenerative medicine: treat or trigger?,Advanced Drug Delivery Reviews

当前位置： X-MOL 学术 › Adv. Drug Deliver. Rev. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Fibrosis in tissue engineering and regenerative medicine: treat or trigger?
Advanced Drug Delivery Reviews ( IF 15.2 ) Pub Date : 2019-07-08 , DOI: 10.1016/j.addr.2019.07.007
Alicia Fernández-Colino ₁ , Laura Iop ₂ , Mónica S Ventura Ferreira ₃ , Petra Mela ₄

Affiliation

Fibrosis is a life-threatening pathological condition resulting from a dysfunctional tissue repair process. There is no efficient treatment and organ transplantation is in many cases the only therapeutic option. Here we review tissue engineering and regenerative medicine (TERM) approaches to address fibrosis in the cardiovascular system, the kidney, the lung and the liver. These strategies have great potential to achieve repair or replacement of diseased organs by cell- and material-based therapies. However, paradoxically, they might also trigger fibrosis. Cases of TERM interventions with adverse outcome are also included in this review. Furthermore, we emphasize the fact that, although organ engineering is still in its infancy, the advances in the field are leading to biomedically relevant in vitro models with tremendous potential for disease recapitulation and development of therapies. These human tissue models might have increased predictive power for human drug responses thereby reducing the need for animal testing.

中文翻译：

组织工程和再生医学中的纤维化：治疗还是引发？

纤维化是由组织修复功能障碍导致的危及生命的病理状况。没有有效的治疗方法，在许多情况下器官移植是唯一的治疗选择。在这里，我们回顾了组织工程和再生医学（TERM）方法，以解决心血管系统，肾脏，肺和肝脏中的纤维化。这些策略具有通过基于细胞和材料的疗法来修复或替换患病器官的巨大潜力。然而，自相矛盾的是，它们也可能引发纤维化。本评价还包括不良结果的TERM干预病例。此外，我们强调以下事实：尽管器官工程学仍处于起步阶段，该领域的进展正在导致具有生物医学相关性的体外模型，这些模型对于疾病的概括和疗法的发展具有巨大的潜力。这些人体组织模型可能对人类药物反应具有增强的预测能力，从而减少了对动物测试的需求。

更新日期：2019-11-18

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11